Cargando…

High Prevalence of Severe Hepatic Fibrosis in Type 2 Diabetic Outpatients Screened for Non-Alcoholic Fatty Liver Disease

Background: Non-alcoholic fatty liver disease (NAFLD) is a highly frequent condition in patients with type 2 diabetes (T2D), but the identification of subjects at higher risk of developing the more severe forms remains elusive in clinical practice. The aim of this study was to evaluate the occurrenc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Asero, Clelia, Giandalia, Annalisa, Cacciola, Irene, Morace, Carmela, Lorello, Giuseppe, Caspanello, Amalia Rita, Alibrandi, Angela, Squadrito, Giovanni, Russo, Giuseppina T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146119/ https://www.ncbi.nlm.nih.gov/pubmed/37109195 http://dx.doi.org/10.3390/jcm12082858

Ejemplares similares

Impact of Sex and Gender on Clinical Management of Patients with Advanced Chronic Liver Disease and Type 2 Diabetes
por: Licata, Anna, et al.
Publicado: (2023)

Hypergammaglobulinemia before Starting DAA Therapy Is A Strong Predictor of Disease Progression in Cirrhotic Patients Even after HCV Clearance
por: Franzè, Maria Stella, et al.
Publicado: (2022)

Over time evaluation of glycaemic control in direct‐acting antiviral‐treated hepatitis C virus/diabetic individuals with chronic hepatitis or with cirrhosis
por: Cacciola, Irene, et al.
Publicado: (2021)

Gender Differences in Diabetic Kidney Disease: Focus on Hormonal, Genetic and Clinical Factors
por: Giandalia, Annalisa, et al.
Publicado: (2021)

Markers of Systemic Inflammation and Apo-AI Containing HDL Subpopulations in Women with and without Diabetes
por: Russo, Giuseppina T., et al.
Publicado: (2014)

Impact of Covid-19 Pandemic on the Effectiveness of Outpatient Counseling in Childhood Obesity Management
por: Corica, Domenico, et al.
Publicado: (2022)

Influence of peroxisome proliferator-activated receptor-γ exon 2 and exon 6 and insulin receptor substrate (IRS)-1 Gly972Arg polymorphisms on insulin resistance and beta-cell function in southern mediterranean women with polycystic ovary syndrome
por: Giandalia, Annalisa, et al.
Publicado: (2018)

Resistin levels and inflammatory and endothelial dysfunction markers in obese postmenopausal women with type 2 diabetes mellitus
por: Giandalia, A., et al.
Publicado: (2021)

Long-Term Influence of Locus of Control and Quality of Life on Metabolic Profile in Elderly Subjects with Type 2 Diabetes
por: Giandalia, Annalisa, et al.
Publicado: (2022)

Impact of Cognitive Reserve and Premorbid IQ on Cognitive and Functional Status in Older Outpatients
por: Quattropani, Maria C., et al.
Publicado: (2021)

Methotrexate Increases Skeletal Muscle GLUT4 Expression and Improves Metabolic Control in Experimental Diabetes
por: Russo, Giuseppina T., et al.
Publicado: (2012)

Sex-Specific Impact of Different Obesity/Metabolic Phenotypes on Long-Term Cardiovascular Outcomes in Acute Coronary Syndrome Patients
por: Imbalzano, Egidio, et al.
Publicado: (2022)

Fatty Liver as Potential Biomarker of Atherosclerotic Damage in Familial Combined Hyperlipidemia
por: Mandraffino, Giuseppe, et al.
Publicado: (2022)

Serum endocan as a predictive biomarker of cardiovascular risk in obese pediatric patients
por: Morace, Carmela, et al.
Publicado: (2023)

GLP-1 Receptor Agonists and Kidney Protection
por: Greco, Eulalia Valentina, et al.
Publicado: (2019)

Arterial Stiffness and Adult Onset Vasculitis: A Systematic Review
por: Lo Gullo, Alberto, et al.
Publicado: (2022)

Role of telemedicine during COVID-19 pandemic in type 2 diabetes outpatients: The AMD annals initiative
por: Russo, Giuseppina T., et al.
Publicado: (2022)

Acute kidney injury in cirrhotic patients undergoing contrast-enhanced computed tomography
por: Filomia, Roberto, et al.
Publicado: (2016)

Antihypertensive Treatment in Diabetic Kidney Disease: The Need for a Patient-Centered Approach
por: Bonino, Barbara, et al.
Publicado: (2019)

Fracture Risk in Type 2 Diabetes: Current Perspectives and Gender Differences
por: Russo, Giuseppina T., et al.
Publicado: (2016)

Corrigendum to “Fracture Risk in Type 2 Diabetes: Current Perspectives and Gender Differences”
por: Russo, Giuseppina T., et al.
Publicado: (2017)

Non-invasive fibrosis assessment in non-alcoholic fatty liver disease
por: Rios, Rafael S., et al.
Publicado: (2020)

Abnormal left ventricular global strain during exercise-test in young healthy smokers
por: Mandraffino, Giuseppe, et al.
Publicado: (2020)

Effects of Lipid Lowering Therapy Optimization by PCSK9 Inhibitors on Circulating CD34+ Cells and Pulse Wave Velocity in Familial Hypercholesterolemia Subjects without Atherosclerotic Cardiovascular Disease: Real-World Data from Two Lipid Units
por: Scicali, Roberto, et al.
Publicado: (2022)

Quality of Life (QoL) in Patients with Chronic Inflammatory Bowel Diseases: How Much Better with Biological Drugs?
por: Bellone, Federica, et al.
Publicado: (2023)

Complements are involved in alcoholic fatty liver disease, hepatitis and fibrosis
por: Lin, Cheng-Jie, et al.
Publicado: (2018)

Progressive Liver Fibrosis in Non-Alcoholic Fatty Liver Disease
por: Ramai, Daryl, et al.
Publicado: (2021)

Are Obese Patients Evaluated for Non-Alcoholic Fatty Liver Disease in an Endocrinology Outpatient Clinic?
por: Irazusta, Florencia, et al.
Publicado: (2021)

PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy
por: Toscano, Arianna, et al.
Publicado: (2022)

Endocan and Circulating Progenitor Cells in Women with Systemic Sclerosis: Association with Inflammation and Pulmonary Hypertension
por: Lo Gullo, Alberto, et al.
Publicado: (2021)

Machine learning to predict progression of non‐alcoholic fatty liver to non‐alcoholic steatohepatitis or fibrosis
por: Ghandian, Sina, et al.
Publicado: (2022)

Current Modalities of Fibrosis Assessment in Non-alcoholic Fatty Liver Disease
por: Cheah, Mark CC, et al.
Publicado: (2017)

Risk Predictors of Advanced Fibrosis in Non-Alcoholic Fatty Liver Disease
por: Olteanu, Vasile-Andrei, et al.
Publicado: (2022)

Non-alcoholic Fatty Liver Disease and Liver Fibrosis during Aging
por: Li, Yuan, et al.
Publicado: (2022)

Silymarin: An option to treat non-alcoholic fatty liver disease
por: Colica, Carmela, et al.
Publicado: (2017)

Expression and Change of miRs 145, 221 and 222 in Hypertensive Subjects Treated with Enalapril, Losartan or Olmesartan
por: Mandraffino, Giuseppe, et al.
Publicado: (2021)

Ficolin-2 Plasma Level Assesses Liver Fibrosis in Non-Alcoholic Fatty Liver Disease
por: Giraudi, Pablo J., et al.
Publicado: (2022)

Hepatic Unsaturated Fatty Acids Are Linked to Lower Degree of Fibrosis in Non-alcoholic Fatty Liver Disease
por: Fridén, Michael, et al.
Publicado: (2022)

Portal lymphadenopathy predicts non-alcoholic steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease
por: Daher, Saleh, et al.
Publicado: (2018)

Reappraisal of fibrosis-4 index and non-alcoholic fatty liver disease fibrosis score for advanced fibrosis in average-risk population
por: Park, Huiyul, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1h3gk19l9ed3tsuaa58c3rqp94